Thurston Springer Miller Herd & Titak Inc. Purchases 405 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Thurston Springer Miller Herd & Titak Inc. lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 22.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,174 shares of the pharmaceutical company’s stock after purchasing an additional 405 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Vertex Pharmaceuticals were worth $1,054,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of VRTX. Mascagni Wealth Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $31,000. Golden State Wealth Management LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at about $37,000. Truvestments Capital LLC increased its stake in Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after acquiring an additional 23 shares during the period. Mpwm Advisory Solutions LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter worth about $40,000. Finally, Midwest Capital Advisors LLC bought a new position in Vertex Pharmaceuticals during the fourth quarter worth about $41,000. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP David Altshuler sold 3,231 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Bank of America raised their target price on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. Wolfe Research cut Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Wednesday, May 7th. Morgan Stanley upped their target price on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 6th. HC Wainwright reissued a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Finally, Royal Bank of Canada boosted their price target on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the company a “sector perform” rating in a research report on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $515.04.

Vertex Pharmaceuticals Trading Down 0.5%

Shares of NASDAQ VRTX opened at $443.82 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The firm has a market capitalization of $113.97 billion, a P/E ratio of -201.74, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The company’s 50 day simple moving average is $465.69 and its 200 day simple moving average is $460.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. During the same period last year, the company earned $4.76 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.